Search Results - "RUBBERT, Andrea"

Anti‐SARS‐CoV‐2 mRNA vaccines as inducers of humoral response against apolipoprotein A‐1? by Vuilleumier, Nicolas, Pagano, Sabrina, Ludewig, Burkhard, Schmiedeberg, Kristin, Haller, Christoph, Kempis, Johannes, Rubbert‐Roth, Andrea

“…Background COVID‐19 and some anti‐SARS‐CoV‐2 vaccines trigger a humoral autoimmune response against a broad range of endogenous components, which may affect…”
Get full text

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis by Rubbert-Roth, Andrea, Enejosa, Jeffrey, Pangan, Aileen L, Haraoui, Boulos, Rischmueller, Maureen, Khan, Nasser, Zhang, Ying, Martin, Naomi, Xavier, Ricardo M

“…In a 24-week trial involving patients with rheumatoid arthritis that was refractory to biologic agents, the JAK1 inhibitor upadacitinib was superior to the…”
Get full text

Discovery of the Ergothioneine Transporter by Gründemann, Dirk, Harlfinger, Stephanie, Golz, Stefan, Geerts, Andreas, Lazar, Andreas, Berkels, Reinhard, Jung, Norma, Rubbert, Andrea, Schömig, Edgar, Cerami, Anthony

“…Variants of the SLC22A4 gene are associated with susceptibility to rheumatoid arthritis and Crohn's disease. SLC22A4 codes for an integral membrane protein,…”
Get full text

Antigen‐presenting human B cells are expanded in inflammatory conditions by Shimabukuro‐Vornhagen, Alexander, García‐Márquez, María, Fischer, Rieke N., Iltgen‐Breburda, Juliane, Fiedler, Anne, Wennhold, Kerstin, Rappl, Gunter, Abken, Hinrich, Lehmann, Clara, Herling, Marco, Wolf, Dominik, Fätkenheuer, Gerd, Rubbert‐Roth, Andrea, Hallek, Michael, Theurich, Sebastian, Bergwelt‐Baildon, Michael

“…Traditionally, B cells have been best known for their role as producers of antibodies. However, in recent years, a growing body of evidence has accumulated…”
Get full text

The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus by Alexander, Tobias, Sarfert, Ramona, Klotsche, Jens, Kühl, Anja A, Rubbert-Roth, Andrea, Lorenz, Hannes-Martin, Rech, Jürgen, Hoyer, Bimba F, Cheng, Qingyu, Waka, Aderajew, Taddeo, Adriano, Wiesener, Michael, Schett, Georg, Burmester, Gerd-Rüdiger, Radbruch, Andreas, Hiepe, Falk, Voll, Reinhard E

“…To investigate whether bortezomib, a proteasome inhibitor approved for treatment of multiple myeloma, induces clinically relevant plasma cell (PC) depletion in…”
Get more information

Relevance of the Organic Cation Transporters 1 and 2 for Antiretroviral Drug Therapy in Human Immunodeficiency Virus Infection by JUNG, Norma, LEHMANN, Clara, RUBBERT, Andrea, KNISPEL, Meike, HARTMANN, Pia, VAN LUNZEN, Jan, STELLBRINK, Hans-Juergen, FAETKENHEUER, Gerd, TAUBERT, Dirk

“…Carrier-mediated transport across cell membranes is an important determinant of activity, resistance, and toxicity of chemotherapeutic agents including…”
Get full text

Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases by Schultz, Olaf, Oberhauser, Frank, Saech, Jasemine, Rubbert-Roth, Andrea, Hahn, Moritz, Krone, Wilhelm, Laudes, Matthias

“…Interleukin-6 (IL-6) is a pro-inflammatory cytokine that has been found to be increased in type 2 diabetic subjects. However, it still remains unclear if these…”
Get full text

Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy by Amstad, Andrea, Papagiannoulis, Eleftherios, Scherer, Almut, Rubbert-Roth, Andrea, Finckh, Axel, Mueller, Ruediger, Dudler, Jean, Möller, Burkhard, Villiger, Peter M, Schulz, Martin M P, Kyburz, Diego

“…JAK Inhibitors (JAKi) are recommended DMARDs for patients with moderate-to-severe RA who failed first-line therapy with methotrexate. There is a lack of data…”
Get full text

A Review of Recent Advances Using Tocilizumab in the Treatment of Rheumatic Diseases by Rubbert-Roth, Andrea, Furst, Daniel E., Nebesky, Jan Michael, Jin, Angela, Berber, Erhan

“…Tocilizumab (TCZ) is the first humanized anti-interleukin-6 (IL-6) receptor monoclonal antibody approved for the treatment of patients with rheumatoid…”
Get full text

Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab by Rubbert-Roth, Andrea, Furst, Daniel E, Fiore, Stefano, Praestgaard, Amy, Bykerk, Vivian, Bingham, Clifton O, Charles-Schoeman, Christina, Burmester, Gerd

“…Anemia is common in patients with rheumatoid arthritis (RA). Higher hemoglobin (Hb) levels may be associated with better clinical outcomes and patient-reported…”
Get full text

Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis by Gilbert, Benoit Thomas P, Lamacchia, Céline, Mongin, Denis, Lauper, Kim, Trunk, Eric, Studer, Olivia, Courvoisier, Delphine S, Rubbert-Roth, Andrea, Kyburz, Diego, Moeller, Burkhard, Finckh, Axel

“…PurposeRheumatoid arthritis (RA) is an insidious autoimmune disease, with an immunological onset years before diagnosis. Early interventions in preclinical…”
Get full text

Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study) by Behrens, Frank, Koehm, Michaela, Rossmanith, Tanja, Alten, Rieke, Aringer, Martin, Backhaus, Marina, Burmester, Gerd R, Feist, Eugen, Herrmann, Eva, Kellner, Herbert, Krueger, Klaus, Lehn, Annette, Müller-Ladner, Ulf, Rubbert-Roth, Andrea, Tony, Hans-Peter, Wassenberg, Siegfried, Burkhardt, Harald

“…To investigate the efficacy and safety of rituximab + LEF in patients with RA. In this investigator-initiated, randomized, double-blind, placebo-controlled…”
Get full text

Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis by Rubbert-Roth, Andrea, Aletaha, Daniel, Devenport, Jenny, Sidiropoulos, Paris N, Luder, Yves, Edwardes, Michael D, Jacobs, Johannes W G

“…Abstract Objective To determine the extent to which disease duration, alone or in combination with other baseline clinical and non-clinical factors, explains…”
Get full text

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions by Smolen, Josef S, Schoels, Monika M, Nishimoto, Norihiro, Breedveld, Ferdinand C, Burmester, Gerd R, Dougados, Maxime, Emery, Paul, Ferraccioli, Gianfranco, Gabay, Cem, Gibofsky, Allan, Gomez-Reino, Juan Jesus, Jones, Graeme, Kvien, Tore K, Murakami, Miho, Betteridge, Neil, Bingham, 3rd, Clifton O, Bykerk, Vivian, Choy, Ernest H, Combe, Bernard, Cutolo, Maurizio, Graninger, Winfried, Lanas, Angel, Martin-Mola, Emilio, Montecucco, Carlomaurizio, Ostergaard, Mikkel, Pavelka, Karel, Rubbert-Roth, Andrea, Sattar, Naveed, Scholte-Voshaar, Marieke, Tanaka, Yoshiya, Trauner, Michael, Valentini, Gabriele, Winthrop, Kevin L, de Wit, Maarten, van der Heijde, Désirée

“…Since approval of tocilizumab (TCZ) for treatment of rheumatoid arthritis (RA) and juvenile idiopathic arthritis (JIA), interleukin 6 (IL-6) pathway inhibition…”
Get more information

Type of mRNA COVID-19 vaccine and immunomodulatory treatment influence humoral immunogenicity in patients with inflammatory rheumatic diseases by Raptis, Catherine E., Berger, Christoph T., Ciurea, Adrian, Andrey, Diego O., Polysopoulos, Christos, Lescuyer, Pierre, Maletic, Tanja, Riek, Myriam, Scherer, Almut, von Loga, Isabell, Safford, Judith, Lauper, Kim, Möller, Burkhard, Vuilleumier, Nicolas, Finckh, Axel, Rubbert-Roth, Andrea

“…Patients with inflammatory rheumatic diseases (IRD) are at increased risk for worse COVID-19 outcomes. Identifying whether mRNA vaccines differ in…”
Get full text

Malignancy in the Upadacitinib Clinical Trials for Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis by Rubbert-Roth, Andrea, Kakehasi, Adriana M., Takeuchi, Tsutomu, Schmalzing, Marc, Palac, Hannah, Coombs, Derek, Liu, Jianzhong, Anyanwu, Samuel I., Lippe, Ralph, Curtis, Jeffrey R.

“…Introduction This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or…”
Get full text

Effectiveness, Tolerability, and Safety of Tofacitinib in Rheumatoid Arthritis: A Retrospective Analysis of Real-World Data from the St. Gallen and Aarau Cohorts by Mueller, Ruediger B., Hasler, Caroline, Popp, Florian, Mattow, Frederik, Durmisi, Mirsada, Souza, Alexander, Hasler, Paul, Rubbert-Roth, Andrea, Schulze-Koops, Hendrik, von Kempis, Johannes

“…Introduction: Tofacitinib is an oral JAK inhibitor indicated for the treatment of rheumatoid arthritis (RA). The efficacy and safety of tofacitinib have been…”
Get full text

Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting by Alten, Rieke, Burkhardt, Harald, Feist, Eugen, Krüger, Klaus, Rech, Juergen, Rubbert-Roth, Andrea, Voll, Reinhard E, Elbez, Yedid, Rauch, Christiane

“…Methotrexate (MTX) remains the anchor drug in rheumatoid arthritis (RA) treatment, but is poorly tolerated or contraindicated in some patients. There is a…”
Get full text

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study by Fleischmann, Roy, Meerwein, Sebastian, Charles-Schoeman, Christina, Combe, Bernard, Hall, Stephen, Khan, Nasser, Carter, Kyle M, Camp, Heidi S, Rubbert-Roth, Andrea

“…ObjectiveTo evaluate the efficacy and safety of upadacitinib over 5 years among patients with rheumatoid arthritis (RA) in a long-term extension (LTE) of the…”
Get full text

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 216 from the SELECT-CHOICE Study by Rubbert-Roth, Andrea, Kato, Koji, Haraoui, Boulos, Rischmueller, Maureen, Liu, Yanxi, Khan, Nasser, Camp, Heidi S., Xavier, Ricardo M.

“…Introduction The safety and efficacy of upadacitinib 15 mg (UPA15) through week 216 was evaluated in patients with rheumatoid arthritis (RA) from the long-term…”
Get full text